Phase 1 trials in pancreatic cancer

Journal of the Pancreas

Volumn 15, Issue 4, 2014, Pages 326-328

  Yu, Esther ^a   Saif, Muhammad Wasif ^a   Huber, Kathryn ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

Clinical trials; Drug therapy; Pancreatic neoplasms; Phase I as topic; Radioimmunotherapy

Indexed keywords

BCR ABL PROTEIN; CLIVATUZUMAB TETRAXETAN Y 90; CONNECTIVE TISSUE GROWTH FACTOR; DASATINIB; ERLOTINIB; FG 3019; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IMATINIB; IRINOTECAN; K RAS PROTEIN; MK 0752; NOTCH RECEPTOR; OXALIPLATIN; PACLITAXEL; PROTEIN P16; PROTEIN P53; SMAD4 PROTEIN; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE;

ANEMIA; ARTICLE; BLOOD CLOTTING DISORDER; BONE MARROW SUPPRESSION; CANCER STAGING; CAUSE OF DEATH; CHRONIC MYELOID LEUKEMIA; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG SAFETY; FATIGUE; HUMAN; HYPERTRANSAMINASEMIA; LUNG NON SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; NAUSEA; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); RADIOIMMUNOTHERAPY; THROMBOCYTOPENIA; TREATMENT RESPONSE; VENOUS THROMBOEMBOLISM; ANALOGS AND DERIVATIVES; METASTASIS; PANCREATIC NEOPLASMS; PATHOLOGY; SURVIVAL; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE I AS TOPIC; DEOXYCYTIDINE; HUMANS; NEOPLASM METASTASIS; PANCREATIC NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84905193244     PISSN: 15908577     EISSN: None     Source Type: Journal    
DOI: 10.6092/1590-8577%2F2683     Document Type: Article

References (15)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin. 2012; 62(1): 10-29. [PMID:22237781]
2. Geer RJ, Brennan MF. Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg. 1993; 165(1): 68-72; discussion 72-3. [PMID:8380315]
3. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, et al., FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011; 364(19): 1817-25. [PMID:21561347]
4. Safran H, Charpentier K, Perez K, Mantripragada K, Austin TC, Nadeem O, Lombardo A, et al. Nab-paclitaxel (nab-P) combined with FOLFOX for advanced pancreatic cancer: A phase I study. J Clin Oncol., 2014; 32:5s (suppl; abstr 4123).
5. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seayet T, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013; 369(18): 1691-703.
6. Reid MD, Saka B, Balci S, Goldblum AS, Adsay NV. Molecular genetics of pancreatic neoplasms and their morphologic correlates: an update on recent advances and potential diagnostic applications. Am J Clin Pathol. 2014; 141(2): 168-80. [PMID:24436263]
7. Du X, Zhao YP, Zhang TP, Zhou L, Chen G, Wang TX, You L, et al., Alteration of the intrinsic apoptosis pathway is involved in Notch-induced chemoresistance to gemcitabine in pancreatic cancer. Arch Med Res. 2014; 45(1): 15-20. [PMID:24316112]
8. Vaccaro V, Melisi D, Bria E, Cuppone F, Ciuffreda L, Pino MS, Gelibter A, et al., Emerging pathways and future targets for the molecular therapy of pancreatic cancer. Expert Opin Ther Targets. 2011; 15(10): 1183-96. [PMID:21819318]
9. Wang Z, Li Y, Kong D, Banerjee S, Ahmad A, Azmi AS, Ali S, et al. Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res. 2009; 69(6): 2400-7. [PMID:19276344]
10. Cook N, Basu B, Smith DM, Gopinathan A, Evans TJ, Steward WP, Hagemannet T, et al. A phase I trial of the γ-secretase inhibitor (GSI) MK- 0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma (PDAC). J Clin Oncol. 2014; 32:5s (suppl; abstr 4116).
11. Aikawa T, Gunn J, Spong SM, Klaus SJ, Korc M, et al., Connective tissue growth factor-specific antibody attenuates tumor growth, metastasis, and angiogenesis in an orthotopic mouse model of pancreatic cancer. Mol Cancer Ther. 2006; 5(5): 1108-16. [PMID:16731742]
12. Picozzi, VJ, Pipas JM, Koong A, Giaccia A, Bahary N, Krishnamurthi SS, Lopez CD, et al. FG-3019, a human monoclonal antibody to connective tissue growth factor (CTGF), with gemcitabine/erlotinib (G/E) in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC). J Clin Oncol. 2014; 32:5s (suppl; abstr 4138).
13. Gulec SA, Cohen SJ, Pennington KL, Zuckier LS, Hauke RJ, Horne H, Wegener WA, et al., Treatment of advanced pancreatic carcinoma with 90Y-Clivatuzumab Tetraxetan: a phase I single-dose escalation trial. Clin Cancer Res. 2011; 17(12): 4091-100. [PMID:21527562]
14. Ocean AJ, Pennington KL, Guarino MJ, Sheikh A, Bekaii-Saab T, Serafini AN, Lee D, et al. Fractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: A phase 1 trial. Cancer. 2012; 118(22): 5497-506.
15. Picozzi VJ, Ramanathan RK, Lowery MA, Ocean AJ, Mitchell EP, O'Neil BH, Guarino MJ, et al. Feasibility and results of a randomized phase b study of fractionated 90-clivatuzumab tetraxetan in patients with metastatic pancreatic cancer having two or more prior therapies. J Clin Oncol. 2014; 32: 5s (suppl; abstr 4026).